The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs -- Joint Program Committee 6 Combat Casualty Care Research Program -- Precision Trauma Care Research Award
In support of the Precision Medicine Initiative, the OASD(HA) identified “precision medicine” as a top science and technical priority for the FY17 DHP RDT&E funds (this is also applicable to FY18 DHP RDT&E funds) and directed DHA to increase the use of “big data” and interdisciplinary approaches, establish a fundamental understanding of military disease and injury, and advance health status assessment, diagnosis, and treatment tailored to individual Service members and beneficiaries. For this Program Announcement/Funding Opportunity, precision medicine is defined as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.”2 Precision medicine pioneers a new model of patient-powered research that aims to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and approaches to select more accurate treatment and prevention strategies that will work best for individual patients.
The intent of the Precision Trauma Care Research Award (PTCRA) is to support research applying precision medicine concepts to trauma care. In order to improve the care of combat casualties, the JPC-6/CCCRP requires capabilities to more accurately diagnose and treat injuries. In general, the field of trauma care progresses as empirical evidence accumulates. Accumulated evidence supports the reduction of unwarranted practice variability (e.g., protocol-driven care). Reduction in practice variability leads to refinement of protocols through improved diagnostic and prognostic indicators that account for patient-specific variables such as injury pattern, comorbidities, demographics, and morphometric data. These approaches are further refined by incorporation of near-term patient-specific variables such as injury progression, response to interventions, and theranostic indicators. The result is a precision medicine approach for trauma care that drives application of interventions to improve outcomes following trauma.
The JPC-6/CCCRP seeks to develop precision medicine approaches for trauma care in the most challenging of environments, including point-of-injury care on the battlefield, deployed healthcare facilities such as casualty collection points, forward surgical teams, and combat support hospitals. This challenge of diverse combat environments and medical capabilities also requires research to develop new solutions to include support for medical providers in the assessment, diagnosis, and treatment of military trauma in out-of-hospital settings (point of injury, austere environment, or en route care) with limited resources through Role 4. Proposed research should consider the entire continuum of trauma care and must be focused on enabling patient-specific interventions and improved outcomes rather than “one size fits all” populationbased tools and techniques.
• Pre-Application Deadline: March 17, 2017
• Invitation to Submit an Application: April 25, 2017
• Application Submission Deadline: June 15, 2017
Areas of Interest
The JPC-6/CCCRP has identified four overarching Focus Areas for funding under this Program Announcement/Funding Opportunity. To meet the intent of the award mechanism, applications MUST propose research that specifically addresses at least one of the four FY18 JPC-6/CCCRP PTCRA Focus Areas. Research not aligned to at least one of these Focus Areas will not be considered for funding.
- Focus Area 1: Improving the Characterization of TBI
- Focus Area 2: Understanding the factors that influence and/or inform patient responsiveness to TBI therapeutic interventions
- Focus Area 3: Understanding the role of environmental and physiological factors impacting injury outcomes
- Focus Area 4: Developing materiel and knowledge products to assist medical and nonmedical care providers in administering individualized combat-related or trauma-induced injury care
This Program Announcement/Funding Opportunity is intended for extramural investigators only. Intramural investigators are required to apply to the FY18 JPC-6/CCCRP Precision Trauma Care Research Award Intramural Program Announcement/Funding Opportunity through eBRAP at https://eBRAP.org/eBRAP/public/Program.htm.
• Independent investigators at all academic levels (or equivalent) are eligible to submit applications. • Cost sharing/matching is not an eligibility requirement. • Eligible investigators must apply through an organization. Organizations eligible to apply include non-DoD Federal agencies, national, international, for-profit, nonprofit, public, and private organizations.
Research supported under this Program Announcement/Funding Opportunity will be funded in three phases, Phase 1 Base, Phase 2 Option.I, and Phase 3 Option.II. Each Phase must be a distinct research effort with a non-overlapping period of performance, research outcomes/milestones, and budget. Research products from a previous Phase shall be leveraged in subsequent Phase(s) if planned. However, proposal of subsequent Option Phases is not required.
• Each Phase has a maximum period of performance of 12 months. The maximum period of performance for all Phases is 36 months.
• Transition from Phase 1 to subsequent Phase(s) will be based on the following criteria: ○ Completion of the research within the 12-month period of performance ○ Documented progress in making data available to the research community ○ Timely submission of quarterly and annual progress reports and quad charts ○ Availability of funds ○ Presentation of research at a minimum of one national research or military relevant conference (for Phase 2 to Phase 3 transition) ○ One or more documented publication submissions (for Phase 2 to Phase 3 transition)
• The anticipated total costs (direct and indirect) budgeted for each Phase will not exceed $1.5 million (M). The maximum anticipated total costs (direct and indirect) for all Phases are $4.5M. Indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding the total cost limitations or using an indirect rate exceeding the organization’s negotiated rate.
• All direct and indirect costs of any subaward must be included in the total direct costs of the primary award.